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Abstract
Background: Sexual hormones have an important role in many hormone-dependant tumors like breast and pros-
tate carcinomas, and also a relationship has been found with bone metabolism and bone tumors. Some studies 
have demonstrated that the expression of hormonal receptors (HR) in osteosarcomas (OS) of long bones is associ-
ated with gender, histological grade, histological type, and possibly may be connection with pathogenesis and evo-
lution. However, to our knowledge there are no studies of HR in osteosarcomas of craniofacial bones (OS-CF).
Objectives: To assess the expression of hormonal receptors in OS-CF. 
Material and Methods: Twenty one cases of OS-CF were included in this study. Clinical outcome was obtained 
from clinical charts. Histological sections were reviewed, and immunohistochemistry studies for estrogen, pro-
gesterone and androgen receptors were performed.
Results: A striking female predominance was found (2:1), with a median age of 35 years. The predominant type 
of OS was osteoblastic (52.4%), and histological grade was high in 86%. Follow-up was obtained in 13 cases and 
ranged from 6 to 118 months (median 29 months). There were 8 patients (61.5%) dead or alive with progressive dis-
ease in the last follow up. Negative expression of HR was found in 19/21 cases; one showed weak nuclear expres-
sion for estrogen receptor, and another for androgen receptor. Progesterone receptor was negative in all cases.
Conclusions: OS-CF mostly affected females, most of them were of the osteoblastic type and of high grade. Hor-
monal expression was practically negative in osteosarcoma of craniofacial bones.
Key words: Osteosarcoma, jaws, estrogen, progesterone, androgen receptors.
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Introduction
Participation of hormones in bone metabolism is a well 
known phenomenon, either in a direct or indirect form. 
Among the most frequently studied ones are: growth 
hormone, prolactin, somatomedin, growth factor similar 
to insulin, paratohormone, thyroid hormones, and ster-
oid hormones. The last three have a role in maintenance 
of integrity of bone structure. The osteoblasts are able 
to produce, from circulating steroids, biologically func-
tional estrogens and androgens (1). There are research 
works directed to clarify the possible participation of 
sex hormones in the pathogenesis of osteosarcoma (OS) 
of long bones (2) that show a predominant occurrence in 
adolescent males. It has been demonstrated that andro-
gens promote osteoblastic differentiation (3), and andro-
gen receptors (AR) have been identified in OS, and that 
they are more abundant in metastatic OS (4), which sug-
gests that anti-androgenic treatment could be useful as a 
therapeutic modality. While AR have been found to be 
more numerous and to have higher affinity in patients 
previously treated with chemotherapy-radiotherapy (5), 
there are some studies that have not demonstrated a di-
rect interaction of androgens and their receptors, sug-
gesting that diverse pathways of action may exist in the 
pathogenesis of bone tumors (6).   
Neoplastic cells of OS show a nuclear pattern of staining 
for AR and estrogen receptors (ER) (7), whereas reactive 
osteoclasts may show cytoplasmic staining for ER (8-11). 
With the purpose of identifying possible prognostic 
factors and treatment guidelines, there have been some 
attempts to correlate expression of HR with several 
clinical and histological signs. The expression of AR 
has been correlated with worse prognosis and a shorter 
metastasis free period after treatment (12).
Other authors (13)  have observed that the expression 
of ER was more intense with better tumor differentia-
tion. On the other hand, Fohr et al. (14) studied the in-
vitro effects of sexual steroids in cell lines of human 
OS, segregating groups according to histological grade 
and patient s´ gender, and no significant differences were 
found. Most published works refer to the expression of 
HR in long bones, but no studies of craniofacial oste-
osarcomas (CF-OS) were found in the literature review. 
Craneofacial bones are embryologically distinct, as they 
evolve from intramembranous ossification, while long 
bones are formed by endochondral ossification.
The objective of the present work was to assess the ex-
pression of HR in CF-OS, and to compare the results 
with those found in studies of OS of the long bones pu-
blished in the literature.
Material and Methods
Twenty-one cases of CF-OS were collected (12 were 
from the pathology archives of the Instituto Nacional de 
Cancerología and 9 from the consultation files of the au-
thors). Inclusion criteria were: cases that had confirmed 
diagnosis of osteosarcoma of the jawbones which have 
enough tissue to perform immunohistochemical analy-
sis with three different hormonal receptors. Those cases 
that had not paraffin-embedded tissue were excluded, as 
well as those cases that were not useful for performing 
the immunohistochemical study due to technical diffi-
culties on their process. 
In 13 cases complete clinical information and follow-
up was available. Clinical stage was evaluated with 
the pathologic findings of surgical resection using the 
TNM system of the American Joint Committee on Can-
cer 2002 (15). The histological slides were reviewed to 
standardize histological criteria. 
Immunohistological studies were performed in archi-
val paraffin embedded tissue using antibodies against 
estrogen receptor (ER) (1:400), progesterone receptor 
(PR) (1:100) and androgen receptor (AR) (1:100) (BIO 
SB Inc. Santa Bárbara CA), with the biotin-streptavi-
din-peroxidase method. The reaction was considered 
positive when the signal was exclusively nuclear, while 
the cytoplasmic reaction was regarded as negative.
Results
The tumors studied in this series occurred with more 
frequency in the female gender (66.7% with a F:M ratio 
of 2:1). The median age of presentation was 35.2 years 
(range 16 to 68 years). The most frequent histological 
type observed was osteoblastic OS (11 cases, 52.4%), 
followed by fibroblastic (7 cases, 33.3%). The majority 
were classified as high-grade tumors (18 cases, 86%) 
(Table 1) and almost half of the patients were in clinical 
stage IIA (Table 2). 
The immunohistochemical studies expressed the fol-
lowing: 19 cases (90.5%) were negative for HR, one 
case showed nuclear signal for ER, another case dis-
played  weak nuclear signal for AR , and all cases were 
negative for PR.
Table 1. Histological features of osteogenic sarcoma 
in the present series (n=21).
TYPE Number of cases (%) 
Osteoblastic 11 ( 52.4 % ) 
Chondroblastic 3 ( 14.3  %) 
Fibroblastic 7 ( 33.3 %) 
GRADE  
Low Grade 3/21 ( 14%) 
High Grade 18/21, (86%). 
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Table 2. Clinical features of jaw osteosarcomas in the present series (n=13).
M= Male, F= Female, L= Left, R= Right, Mand= Mandible, Max= Maxilla, Hemimandiblect= Hemimandibulectomy, Maxillect= 
Maxillectomy, RT= Radiotherapy, CT= Chemotherapy,  Mets= Metastasis, LN= Lymph nodes, Recurr= Recurrence, M= Months, 
AW= Alive and well,  AWD= alive with disease, DOD dead of disease.
No. Age 
and
gender 
Location Size Stage Treatment Outcome Follow-up 
1 44/M R Mand 7 cm IIA Hemimandibulectomy + RT Recurrence 10M 
AWD
10M
2 28/F R Mand 11cm III Hemimadiblect. + RT 
Recurr. 
5 M 
Mets LN 
AWD 
5 M 
3 16/F L Max 15cm IIB- Maxillect + RT/CT Recurr. 14M 
AW
20M
4 31/M R Max 4cm IIA CT + Maxillect + RT RT/CT 
Recurr 
10 M AWD 
5 32/F R Mand 12cm IIB CT/RT+ partial Mandiblect Mets 9M AWD 9M 
6 61/F R Mand 5 cm IIA Hemimandiblect + CT  AW 60M 
7 17/F Mand.
Midline 
9 cm IIB Subtotal Mandiblect  + CT 
Mets lung 
29M
Mets thorax 37M 
DOD 
51 M 
8 38/F L Mand 9 cm IIB Total Mandiblect + CT 
Recurr. 
Mets LN 
10 M 
AWD 
12 M 
9 68/F L Mand 6 cm IVB Total Mandiblect + RT 
Persist.
Mets LN 
AW
19 M 
10 ?/F R Max 1 cm - Total Maxillect + CT 
Recurr. At  16, 81, 
108 and 117 M 
AWD 
118 M 
11 21/M R Max 6 cm IA
RT + Maxillect 
(margins +) + CT 
 AWD 
13 M 
12 37/F L Mand 4.5cm IIA Hemimandiblect + CT/RT Mets Lung 
26 M 
AW
33M
13 17/M - 8 cm IIA CT+ radical surg + CT 
Recurr. 
Mets lung 
11 M 
AW
18 M 
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Complete clinical information was obtained in 13 cases 
with follow-up ranging from 7 to 109 months (median: 
30 months). Seven patients (53.8%) developed metastas-
es, three in the cervical lymph nodes, two in the lung, 
one in the lung and thorax and one in an unspecified 
site. Rapid progression occurred in 4 patients (30%) and 
eight cases (61.5%) either died of disease or presented 
advanced disease in the last follow-up (Table 2). 
Discussion
CF-OS are uncommon tumors, comprising 6-10% of all 
OS, and they affect preferentially the body of the man-
dible (16,17).  The highest incidence is in the 3rd and 4th 
decades of life. In this study the median age of presenta-
tion was 32 years, which is similar to previous reports, 
although there were two patients under the age of 20 (16 
and 17 years, respectively).
In the present series, a frank predominance in women 
was found with a F:M ratio of 2:1, while in the literature 
CF-OS is reported to be more frequent in males, although 
a slight female predominance has been reported in se-
ries from Mexico (18) and Japan (19). At the present time 
we can not speculate if this gender tendency is related 
to socio-demographic and racial factors or if it is due to 
intrinsic conditions of the neoplasia or the bone type.
Many series in the literature report that the chondro-
blastic variety is the most frequent histological type of 
CF-OS (17), which is in disagreement with the present 
work in which the predominant type was osteoblastic, 
but the cause of this difference is unknown. The most 
frequent consequence of treatment failure in CF-OS is 
local recurrence, which occur in up to 50%, and metas-
tases in 30% within two years after resection of the pri-
mary tumor. The favorite metastatic site is lung (25%) 
followed by lymph nodes and central nervous system 
(20,21). Our recurrence rate was 30%, and metastases 
occurred in 38%. 
There are series of CF-OS in the literature that report a 
great proportion of high-grade tumors (17-19), with fre-
quencies ranging from 54% to 90%, similar to the 86% 
figure found in the present work. 
At puberty, steroid sex hormones stimulate endochon-
dral bone formation of long bones. OS of these bones 
is more frequently seen at this age, and the expression 
of HR has been well demonstrated; however, in the 
adult, bone maintenance is based mainly in androgen 
metabolism in men and also in women.  In has been 
reported that in non-neoplastic tissue of long bones, the 
osteoblasts show nuclear expression of ER, while in os-
teoclasts it is cytoplasmic (8-10).
It is accepted that in the appendicular long bones the os-
sification is endochondral, i.e. from the cartilage at the 
bone ends. On the other hand, ossification of cranial flat 
bones is of membranous type, by direct differentiation 
of mesenchymal cells into osteoblasts; however, in some 
of cranio-facial bones there are spots of endochondral 
ossification (22-27) and, depending on its origin axial or 
apendicular, bone development has complex molecular 
signaling pathways for its mineralization, involving tis-
sular growth factors and hormones that play an impor-
tant role (28); however, their precise actions in cranio-
facial bone development is not completely understood, 
as the effect of sex hormones in endochondral minerali-
zation has been explored only in the mandibular con-
dyle (22), and to our knowledge, there are no reports on 
the action of steroid hormones in membranous bones.
In the present series there was absence of expression 
of HR in the majority of cases, as only in two of them 
weakly positive signals for AR and ER were detected 
respectively. Other two cases showed  osteoclasts with 
cytoplasmic expression for HR.
We believe that the low expression of HR may be related 
to the type of bone studied, and perhaps the focal signal 
of HR is due to transitory endochondral mineralization 
in the cranio-facial bones (29). Another explanation 
would be that as membranous ossification is originated 
in a pluripotential cell, the expresión of HR could be 
present but with a lesser intensity.
The expression of HR in long bones in relationship to dif-
ferentiation has been previously studied; in this respect, 
Liu et al. (13) observed that the intensity of the reaction 
was in direct relationship with tumor differentiation.  
In conclusion, our results indicate that HR have negative 
or minimal expression in CF-OS, which are in discre-
pancy with studies that have explored HR in OS of the 
long bones. The reason for this difference could be the 
differences in the mechanism of ossification and bone 
metabolism that occurs in jaws. Other differences with 
respect to most previous publications are the female 
predominance (2:1), and the osteoblastic predominance 
found in our series. 
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